ASSESSMENT OF DIASTOLIC FUNCTION OF THE LEFT VENTRICLE, INTIMA-MEDIA THICKNESS AND EXERCISE TOLERANCE IN CHD PATIENTS TAKING BISOPROLOL AND IVABRADINE

Aim. To assess the parameters of the left ventricle diastolic function, intima-media thickness, exercise tolerance in stable angina and CHF I-III FC (NYHA) with sinus rhythm and HR >70 bpm; with the signs of diastolic dysfunction of I type and EF >50% taking bisoprolol and ivabradine (...

Full description

Bibliographic Details
Main Authors: G. I. Khairutdinova, G. V. Babushkina
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC  2016-03-01
Series:Российский кардиологический журнал
Subjects:
Online Access:https://russjcardiol.elpub.ru/jour/article/view/738
id doaj-335134b320e249e5939d5203788021d3
record_format Article
spelling doaj-335134b320e249e5939d5203788021d32021-07-28T14:02:26Zrus«FIRMA «SILICEA» LLC Российский кардиологический журнал1560-40712618-76202016-03-0103879110.15829/1560-4071-2016-3-87-91647ASSESSMENT OF DIASTOLIC FUNCTION OF THE LEFT VENTRICLE, INTIMA-MEDIA THICKNESS AND EXERCISE TOLERANCE IN CHD PATIENTS TAKING BISOPROLOL AND IVABRADINEG. I. Khairutdinova0G. V. Babushkina1Bashkirsky State Medical University of the Ministry of Health; LLC Cardioneurological Dispensary; Healthcare Institution CCH №13Bashkirsky State Medical University of the Ministry of HealthAim. To assess the parameters of the left ventricle diastolic function, intima-media thickness, exercise tolerance in stable angina and CHF I-III FC (NYHA) with sinus rhythm and HR >70 bpm; with the signs of diastolic dysfunction of I type and EF >50% taking bisoprolol and ivabradine (Coraxan®, Les Laboratories Servier, France).Material and methods. Totally, 73 patients studied with stable angina of II and III FC with CHF I-III FC (NYHA) at the age 40-65 y.o., HR >70 bpm and I type diastolic dysfunction of the left ventricle (LV), during 12 weeks.Patients were randomized to 3 groups: group A consisted of 27 patients who received bisoprolol with dose titration up to 10 mg per day; group B — 24 patients taking combination therapy with bisoprolol and Coraxan®, group В — 22 patients taking Coraxan® up to 15 mg per day. Patients of all groups received basic therapy by angiotensin converting enzyme inhibitors (ACEi), antiplatelet drugs, statins, short acting nitrates for angina attacks. To assess the results of the study, 6-minute walking test was performed, with echocardiography and Doppler, electrocardiography (ECG), ultrasound duplex scan of arteries of the head (UDSAH).Results. By the results of our study, in all three groups there was target HR achievement, that was followed by statistically significant increase of exercise tolerance by the results of 6-minute walking test, most prominent in the group of patients taking bisoprolol with Coraxan®.Echo in three groups at baseline and in 12 week showed significant deceleration of diastolic flow through mitral valve only in the group receiving Coraxan® (р<0,05), and increase of the velocity of early diastolic filling in this group (р<0,01).the results of UDSAH, there was tendency to decrease of intima-media thickness in all groups.Conclusion. In stable angina patients with CHF I-III FC taking complex therapy with β-blocker bisoprolol and/or Coraxan®, was the target level of HR reached, that retained for 12 weeks and was followed by increase of exercise tolerance (p<0,05 to <0,01). In the group of patients who received ivabradine, there was improvement of the values of diastolic function of the left ventricle that helped to increase effective duration of diastolic filling of the left ventricle.https://russjcardiol.elpub.ru/jour/article/view/738chronic heart failurediastolic dysfunctionangina pectorisheart rate6-minute walking testintima-media complex
collection DOAJ
language Russian
format Article
sources DOAJ
author G. I. Khairutdinova
G. V. Babushkina
spellingShingle G. I. Khairutdinova
G. V. Babushkina
ASSESSMENT OF DIASTOLIC FUNCTION OF THE LEFT VENTRICLE, INTIMA-MEDIA THICKNESS AND EXERCISE TOLERANCE IN CHD PATIENTS TAKING BISOPROLOL AND IVABRADINE
Российский кардиологический журнал
chronic heart failure
diastolic dysfunction
angina pectoris
heart rate
6-minute walking test
intima-media complex
author_facet G. I. Khairutdinova
G. V. Babushkina
author_sort G. I. Khairutdinova
title ASSESSMENT OF DIASTOLIC FUNCTION OF THE LEFT VENTRICLE, INTIMA-MEDIA THICKNESS AND EXERCISE TOLERANCE IN CHD PATIENTS TAKING BISOPROLOL AND IVABRADINE
title_short ASSESSMENT OF DIASTOLIC FUNCTION OF THE LEFT VENTRICLE, INTIMA-MEDIA THICKNESS AND EXERCISE TOLERANCE IN CHD PATIENTS TAKING BISOPROLOL AND IVABRADINE
title_full ASSESSMENT OF DIASTOLIC FUNCTION OF THE LEFT VENTRICLE, INTIMA-MEDIA THICKNESS AND EXERCISE TOLERANCE IN CHD PATIENTS TAKING BISOPROLOL AND IVABRADINE
title_fullStr ASSESSMENT OF DIASTOLIC FUNCTION OF THE LEFT VENTRICLE, INTIMA-MEDIA THICKNESS AND EXERCISE TOLERANCE IN CHD PATIENTS TAKING BISOPROLOL AND IVABRADINE
title_full_unstemmed ASSESSMENT OF DIASTOLIC FUNCTION OF THE LEFT VENTRICLE, INTIMA-MEDIA THICKNESS AND EXERCISE TOLERANCE IN CHD PATIENTS TAKING BISOPROLOL AND IVABRADINE
title_sort assessment of diastolic function of the left ventricle, intima-media thickness and exercise tolerance in chd patients taking bisoprolol and ivabradine
publisher «FIRMA «SILICEA» LLC 
series Российский кардиологический журнал
issn 1560-4071
2618-7620
publishDate 2016-03-01
description Aim. To assess the parameters of the left ventricle diastolic function, intima-media thickness, exercise tolerance in stable angina and CHF I-III FC (NYHA) with sinus rhythm and HR >70 bpm; with the signs of diastolic dysfunction of I type and EF >50% taking bisoprolol and ivabradine (Coraxan®, Les Laboratories Servier, France).Material and methods. Totally, 73 patients studied with stable angina of II and III FC with CHF I-III FC (NYHA) at the age 40-65 y.o., HR >70 bpm and I type diastolic dysfunction of the left ventricle (LV), during 12 weeks.Patients were randomized to 3 groups: group A consisted of 27 patients who received bisoprolol with dose titration up to 10 mg per day; group B — 24 patients taking combination therapy with bisoprolol and Coraxan®, group В — 22 patients taking Coraxan® up to 15 mg per day. Patients of all groups received basic therapy by angiotensin converting enzyme inhibitors (ACEi), antiplatelet drugs, statins, short acting nitrates for angina attacks. To assess the results of the study, 6-minute walking test was performed, with echocardiography and Doppler, electrocardiography (ECG), ultrasound duplex scan of arteries of the head (UDSAH).Results. By the results of our study, in all three groups there was target HR achievement, that was followed by statistically significant increase of exercise tolerance by the results of 6-minute walking test, most prominent in the group of patients taking bisoprolol with Coraxan®.Echo in three groups at baseline and in 12 week showed significant deceleration of diastolic flow through mitral valve only in the group receiving Coraxan® (р<0,05), and increase of the velocity of early diastolic filling in this group (р<0,01).the results of UDSAH, there was tendency to decrease of intima-media thickness in all groups.Conclusion. In stable angina patients with CHF I-III FC taking complex therapy with β-blocker bisoprolol and/or Coraxan®, was the target level of HR reached, that retained for 12 weeks and was followed by increase of exercise tolerance (p<0,05 to <0,01). In the group of patients who received ivabradine, there was improvement of the values of diastolic function of the left ventricle that helped to increase effective duration of diastolic filling of the left ventricle.
topic chronic heart failure
diastolic dysfunction
angina pectoris
heart rate
6-minute walking test
intima-media complex
url https://russjcardiol.elpub.ru/jour/article/view/738
work_keys_str_mv AT gikhairutdinova assessmentofdiastolicfunctionoftheleftventricleintimamediathicknessandexercisetoleranceinchdpatientstakingbisoprololandivabradine
AT gvbabushkina assessmentofdiastolicfunctionoftheleftventricleintimamediathicknessandexercisetoleranceinchdpatientstakingbisoprololandivabradine
_version_ 1721269202867716096